Recurrent Glioblastoma Clinical Trials

58 recruitingLast updated: June 18, 2026

There are 58 actively recruiting recurrent glioblastoma clinical trials across 16 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3. Top locations include Boston, Massachusetts, United States, New York, New York, United States, San Francisco, California, United States. Updated daily from ClinicalTrials.gov.


Recurrent Glioblastoma Trials at a Glance

58 actively recruiting trials for recurrent glioblastoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 1 with 33 trials, with the heaviest enrollment activity in Boston, New York, and San Francisco. Lead sponsors running recurrent glioblastoma studies include National Cancer Institute (NCI), Mayo Clinic, and City of Hope Medical Center.

Browse recurrent glioblastoma trials by phase

Treatments under study

About Recurrent Glioblastoma Clinical Trials

Looking for clinical trials for Recurrent Glioblastoma? There are currently 47 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Glioblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Glioblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 58 trials

Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 1

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

GlioblastomaGliomaRecurrent Glioblastoma+2 more
Kailin Yang, MD, PhD45 enrolled1 locationNCT07541781
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliomas
Alpha Tau Medical LTD.10 enrolled3 locationsNCT06910306
Recruiting
Early Phase 1

Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeGlioblastoma (GBM)Recurrent Glioblastoma+1 more
Beijing Tiantan Hospital5 enrolled2 locationsNCT07648823
Recruiting
Phase 1Phase 2

Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma

Glioblastoma (GBM)Recurrent GlioblastomaNewly Diagnosed Glioblastoma+1 more
Trogenix ltd68 enrolled2 locationsNCT07346144
Recruiting
Phase 1

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1Phase 2

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Recruiting
Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 1

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 1

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

Recurrent Glioblastoma
University of Florida24 enrolled1 locationNCT06389591
Recruiting
Phase 1

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Recurrent Glioblastoma
University of Pennsylvania12 enrolled1 locationNCT07209241
Recruiting
Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 2

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
BioNTech SE75 enrolled6 locationsNCT07297212
Recruiting
Phase 1

Sonodynamic Therapy in Patients With Recurrent GBM

GBMGlioblastoma MultiformeRecurrent Glioblastoma
Shayan Moosa, MD11 enrolled1 locationNCT06039709
Recruiting
Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07551336
Recruiting
Phase 2

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Recurrent Glioblastoma
Duke University80 enrolled4 locationsNCT06069726
Recruiting
Early Phase 1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Recurrent Glioblastoma
Huashan Hospital10 enrolled1 locationNCT07538128
Recruiting
Phase 2

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled324 locationsNCT06325683